Immunotherapy for lung cancer: for whom the bell tolls?

Abstract

Lung cancer is the leading cause of cancer-related death and accounts for approximately 30% of all cancer deaths. Despite the recent developments in personalized therapy, the prognosis in lung cancer is still very poor. Immunotherapy is now emerging as a new hope for patients with lung cancer. It is well known that standard chemotherapeutic regimens have devastating effects for the patient's immune system. Therefore, the aim of immunotherapy is to specifically enhance the immune response against the tumour. Recently, many trials addressed the role of such therapies for metastatic non-small cell lung cancer (NSCLC) treatment: ipilimumab, tremelimumab, nivolumab and pembrolizumab are immunotherapeutic agents of high relevance in this field. Anti-tumour vaccines, as well as dendritic cell-based therapies, have emerged as potent inducers of immune response against the tumour. Herein, we will review some of the most promising cancer immunotherapies, highlighting their advantages and try to understand, in an immunological perspective, the missteps associated with the current treatments for cancer.

Profiling cancer testis antigens in non–small-cell lung cancer

“…As a proof of concept, so-called checkpoint inhibitors have been approved for the treatment of advanced NSCLC with impressive long-lasting tumor response (8). Along with antibody-based modalities, vaccination is also used as an immune modulatory approach (9)(10)(11). In principal, all cancer immunotherapies share the concept that the immune system can exclusively attack cancer cells but spare normal cells.…”

Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data

“…Additionally, current standard treatment options involve surgery, chemotherapy, radiation therapy, and targeted therapy. [5][6][7][8][9][10] In recent decades, the biological behaviors of NSCLC and molecular targeting therapies for diagnosis and treatment have undergone remarkable developments. [11][12][13][14] Despite these efforts and improvements, the diagnosis and prognosis of patients remain unsatisfactory.…”

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis

“…Non-small cell lung cancer (NSCLC) is the major type of lung cancer, which accounts for approximately 85% of all cases2. However, the treatment and prognosis of NSCLC are far from satisfactory.…”